- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | NYRADA INC.: Cleansing Statement | - | ASX | ||
| Do | NYRADA INC.: Application for quotation of securities - NYR | - | ASX | ||
| NYRADA INC Aktie jetzt für 0€ handeln | |||||
| Mi | NYRADA INC.: Final Director's Interest Notice | - | ASX | ||
| Mi | NYRADA INC.: Change of Director's Interest Notice | - | ASX | ||
| Mi | NYRADA INC.: Notification of cessation of securities - NYR | 2 | ASX | ||
| Mi | NYRADA INC.: Results of Meeting | - | ASX | ||
| Di | NYRADA INC.: AGM Chair Address | - | ASX | ||
| Di | NYRADA INC.: AGM Presentation | - | ASX | ||
| So | NYRADA INC.: Investor Presentation and CEO AGM Presentation | - | ASX | ||
| 07.11. | NYRADA INC.: Upcoming Release of Securities from Voluntary Escrow | - | ASX | ||
| 05.11. | NYRADA INC.: Cleansing Statement | - | ASX | ||
| 05.11. | NYRADA INC.: Application for quotation of securities - NYR | - | ASX | ||
| 03.11. | NYRADA INC.: Cleansing Statement | - | ASX | ||
| 03.11. | NYRADA INC.: Application for quotation of securities - NYR | - | ASX | ||
| 22.10. | NYRADA INC.: Cleansing Statement | - | ASX | ||
| 22.10. | NYRADA INC.: Application for quotation of securities - NYR | - | ASX | ||
| 21.10. | NYRADA INC.: Quarterly Activities Report and Appendix 4C | - | ASX | ||
| 13.10. | NYRADA INC.: Nyrada Selects Accelagen as CRO for Phase IIa Clinical Trial | - | ASX | ||
| 08.10. | NYRADA INC.: Notification of cessation of securities - NYR | 1 | ASX | ||
| 08.10. | NYRADA INC.: 2025 AGM Letter to Shareholders, Notice of Meeting & Proxy | 1 | ASX |
1 2 3 4 Weiter >>
69 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| STRUCTURE THERAPEUTICS | 35,000 | -2,70 % | Structure Therapeutics stock holds Outperform rating at BMO ahead of key data | ||
| BEAM THERAPEUTICS | 21,660 | 0,00 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 22,860 | -2,39 % | Arcutis completes enrollment in infant atopic dermatitis study | ||
| AVIDITY BIOSCIENCES | 70,81 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 18,260 | 0,00 % | Summit Therapeutics Inc. - 8-K, Current Report | ||
| COGENT BIOSCIENCES | 33,810 | 0,00 % | Aktien New York: Gewinne dank Signalen für Shutdown-Ende | NEW YORK (dpa-AFX) - An den US-Börsen knüpfen die Kurse am Montag mit einer Erholung an die späte Kursstabilisierung vom Freitag an. Wie schon zuvor in Asien und Europa hellten Anzeichen für eine mögliche... ► Artikel lesen | |
| BIONTECH | 88,55 | -0,84 % | BioNTech: Analysten sehen Aktie nach Zahlen im neuen Licht | Die jüngsten Quartalszahlen von BioNTech führten in dieser Woche zu unterschiedlichen Einschätzungen zweier Analystenhäuser. Während UBS das Kursziel leicht anhebt, bleibt Jefferies deutlich positiver.... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 44,290 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | - Submission of New Drug Application (NDA) for lorundrostat planned for late-2025/Q1 2026 - - Completed enrollment in Explore-OSA trial; topline results anticipated in Q1 2026 - - Conference call... ► Artikel lesen | |
| EVOTEC | 5,138 | -5,76 % | Nel ASA: Insider kauft Aktien - Evotec, Newron, Rheinmetall, SUSS und ThyssenKrupp im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| ANNEXON | 2,680 | 0,00 % | Annexon prices public offering of shares at $2.60 each | ||
| ARS PHARMACEUTICALS | 8,410 | 0,00 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy (epinephrine nasal spray) | $32.5 million in revenue, including $31.3 million in neffy U.S. net product revenue in third quarter of 2025 Continued U.S. product growth driven by direct-to-consumer (DTC) investments and real-world... ► Artikel lesen | |
| LENZ THERAPEUTICS | 26,510 | 0,00 % | LENZ Therapeutics, Inc.: LENZ Therapeutics Announces Commercial Product Availability of VIZZ in the United States | VIZZ sample distribution initiated nationwide to Eye Care Professionals Commercial product shipments to be initiated in October to consumers with broad product availability by mid-Q4 2025 VIZZ is... ► Artikel lesen | |
| UPSTREAM BIO | 23,340 | 0,00 % | Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress | - Positive top-line results from VIBRANT Phase 2 trial of verekitug in CRSwNP reported in September showed statistically significant and clinically meaningful effects on primary and key secondary... ► Artikel lesen | |
| ARCELLX | 87,28 | 0,00 % | J&J, Legend withdraw ASH abstract assessing Carvykti against Gilead, Arcellx's rival CAR-T | ||
| PRAXIS PRECISION MEDICINES | 178,20 | 0,00 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen |
Das Unternehmen NYRADA INC CDIS kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NYRADA INC CDIS finden Sie auf Wallstreet Online.